The startup has developed a target-identification and drug-discovery platform that utilizes patient-derived and genetically engineered neural cell types to create specialized cell-based assays. This technology aims to facilitate the development of effective treatments for neurological disorders, addressing the significant unmet medical needs in this area.
Funding
$6.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CVLVFounders
Product
Problem
The pharmaceutical industry faces significant challenges in CNS drug discovery due to the high attrition rate of novel drugs during clinical development. This is largely attributed to the lack of biologically relevant in vitro models that accurately predict drug efficacy and potential neurotoxicity in humans. Traditional animal models often fail to replicate human-specific neural phenotypes, leading to unreliable preclinical testing results.
Solution
NeuCyte addresses these challenges with its proprietary SynFire® technology, which generates human induced pluripotent stem cell (iPSC)-derived neural cells. This technology enables the development of highly functional, human-relevant in vitro platforms for CNS drug discovery. NeuCyte's platform facilitates target identification and validation, efficacy testing, neurotoxicity assessment, and disease modeling using patient-derived and genetically engineered neural cell types. By modeling neurological and neurodegenerative disorders with unique cell-based assays, NeuCyte aims to accelerate and optimize the discovery of effective treatments for conditions like Alzheimer's disease, ALS, Epilepsy, and Fragile X Syndrome. The SynFire® technology allows for complex electrophysiological and morphological readouts, providing a more reliable predictor of drug efficacy and neural safety compared to traditional animal models.
Target Audience
NeuCyte's primary customers include pharmaceutical companies, biotechnology firms, and academic research institutions involved in CNS drug discovery and development, as well as researchers studying neurological and neurodegenerative disorders.
Features
- SynFire® technology for generating human iPSC-derived neurons, including excitatory and inhibitory neurons, and astrocytes
- Proprietary in vitro human neural platform for complex electrophysiological and morphological readouts
- Capability to create defined iN/Astroglial co-cultures and 3D brain assembloids
- Disease modeling using patient-derived and genetically engineered neural cell types
- Functional assays for measuring neuronal survival, axonal outgrowth, dendritic arborization, and synapse formation
- High-content imaging for identifying morphological phenotypes associated with neurological diseases
- Microfluidics-based high-throughput drug-screening platform for Alzheimer's Disease/Alzheimer's Disease-related Dementias (AD/ADRD)
- Capability to integrate microglia into 3D human iPSC-derived brain microphysiological systems for disease modeling